UroFem receives ACC approval

UroFem receives ACC approval

September 30 2016

UroFem 1000mg d-mannose tablets are now an approved product, meaning UroFem is funded for people eligible under Accident Compensation Corporation (ACC).

 

Urinary Tract Infections (UTIs) affect a large number of people that have received an accident related injury, including trauma and burns. People most affected include those with a spinal cord injury and those that require regular or ongoing use of a catheter.

 

Often repeated UTIs lead to drug resistant infections which are significantly more difficult to manage.

 

Importantly now UroFem will be made available to aid a healthy urinary tract and bladder in these groups.

 

“The addition of UroFem reflects the growing clinical data for UroFem in UTI prevention. Against this backdrop is that Doctors, nurses, pharmacists and consumers are realising that the myth of cranberry related products being effective, is untrue. We hope for New Zealand based research of UroFem in higher risk people in future” Julia Reese, regulatory affairs.

 

UroFem d-mannose tablets are available in the medical consumable list product code 7004495. For queries and requests please contact your ACC case manager.

Te Arai BioFarma is a proud supplier to ACC with the vendor code VAT291

 

< Back to News